PGEN vs. DNLI, ARWR, BLTE, ARQT, TARS, HRMY, JANX, TVTX, APGE, and IRON
Should you be buying Precigen stock or one of its competitors? The main competitors of Precigen include Denali Therapeutics (DNLI), Arrowhead Pharmaceuticals (ARWR), Belite Bio (BLTE), Arcutis Biotherapeutics (ARQT), Tarsus Pharmaceuticals (TARS), Harmony Biosciences (HRMY), Janux Therapeutics (JANX), Travere Therapeutics (TVTX), Apogee Therapeutics (APGE), and Disc Medicine (IRON). These companies are all part of the "pharmaceutical products" industry.
Precigen vs.
Precigen (NASDAQ:PGEN) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, community ranking, earnings, valuation and analyst recommendations.
In the previous week, Precigen had 13 more articles in the media than Denali Therapeutics. MarketBeat recorded 21 mentions for Precigen and 8 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.31 beat Precigen's score of 0.04 indicating that Denali Therapeutics is being referred to more favorably in the news media.
Precigen has higher earnings, but lower revenue than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.
33.5% of Precigen shares are held by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are held by institutional investors. 44.9% of Precigen shares are held by company insiders. Comparatively, 7.9% of Denali Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Denali Therapeutics received 28 more outperform votes than Precigen when rated by MarketBeat users. Likewise, 68.48% of users gave Denali Therapeutics an outperform vote while only 67.44% of users gave Precigen an outperform vote.
Precigen currently has a consensus target price of $7.00, suggesting a potential upside of 326.83%. Denali Therapeutics has a consensus target price of $37.20, suggesting a potential upside of 161.97%. Given Precigen's stronger consensus rating and higher possible upside, equities analysts clearly believe Precigen is more favorable than Denali Therapeutics.
Precigen has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500. Comparatively, Denali Therapeutics has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500.
Denali Therapeutics has a net margin of 0.00% compared to Precigen's net margin of -3,521.68%. Denali Therapeutics' return on equity of -32.94% beat Precigen's return on equity.
Summary
Denali Therapeutics beats Precigen on 10 of the 19 factors compared between the two stocks.
Get Precigen News Delivered to You Automatically
Sign up to receive the latest news and ratings for PGEN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Precigen Competitors List
Related Companies and Tools
This page (NASDAQ:PGEN) was last updated on 3/28/2025 by MarketBeat.com Staff
Buy PGEN Stock Free PGEN Stock Alerts